A phase II study of PXD101 (NSC-726630) in relapsed and refractory aggressive B-cell lymphomas.

Trial Profile

A phase II study of PXD101 (NSC-726630) in relapsed and refractory aggressive B-cell lymphomas.

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Jun 2014

At a glance

  • Drugs Belinostat (Primary)
  • Indications B cell lymphoma; Burkitt's lymphoma; Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 May 2012 Results to be presented at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO-2012), according to a Spectrum Pharmaceuticals media release.
    • 20 May 2009 Planned end date changed from 1 Feb 2007 to 1 May 2010 as reported by ClinicalTrials.gov.
    • 20 May 2009 Status changed from suspended to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top